Hyloris Pharmaceuticals SA
XBRU:HYL

Watchlist Manager
Hyloris Pharmaceuticals SA Logo
Hyloris Pharmaceuticals SA
XBRU:HYL
Watchlist
Price: 5.74 EUR -1.03% Market Closed
Market Cap: 160.7m EUR
Have any thoughts about
Hyloris Pharmaceuticals SA?
Write Note

Hyloris Pharmaceuticals SA
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hyloris Pharmaceuticals SA
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Hyloris Pharmaceuticals SA
XBRU:HYL
Cost of Revenue
-€93k
CAGR 3-Years
14%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Ucb SA
XBRU:UCB
Cost of Revenue
-€1.7B
CAGR 3-Years
-8%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Financiere de Tubize SA
XBRU:TUB
Cost of Revenue
-€2m
CAGR 3-Years
-25%
CAGR 5-Years
-6%
CAGR 10-Years
15%
No Stocks Found

Hyloris Pharmaceuticals SA
Glance View

Market Cap
160.7m EUR
Industry
Pharmaceuticals

Hyloris Pharmaceuticals SA engages in the development and reformulating of pharmaceutical products. The company is headquartered in Liege, Liege and currently employs 14 full-time employees. The company went IPO on 2020-06-29. Its focus is on re-engineering cardiovascular products. Additionally, it also further develops and improves already-approved pharmaceuticals and established products, creating new and different solutions. The Company’s diverse product-development portfolio spans a wide range of therapeutic indications and dosage forms.

HYL Intrinsic Value
4.38 EUR
Overvaluation 24%
Intrinsic Value
Price

See Also

What is Hyloris Pharmaceuticals SA's Cost of Revenue?
Cost of Revenue
-93k EUR

Based on the financial report for Dec 31, 2023, Hyloris Pharmaceuticals SA's Cost of Revenue amounts to -93k EUR.

What is Hyloris Pharmaceuticals SA's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-7%

Over the last year, the Cost of Revenue growth was 1%. The average annual Cost of Revenue growth rates for Hyloris Pharmaceuticals SA have been 14% over the past three years , -7% over the past five years .

Back to Top